Drugs & Targets FDA revokes authorization of Red No. 3 in food and ingested drugs January 17, 2025Vol.51 No.02
Drugs & Targets FDA grants Rare Pediatric Disease designation for THIO in pediatric high-grade gliomas January 17, 2025Vol.51 No.02
Drugs & Targets N-Power Medicine acquires Syapse to expand network for oncology clinical research, trials January 17, 2025Vol.51 No.02
Drugs & Targets MAIA Biotechnology, BeiGene announce clinical supply agreement January 17, 2025Vol.51 No.02
Drugs & Targets Caris, Ontada form collaboration to advance molecular research, cancer care January 17, 2025Vol.51 No.02
Drugs & Targets FDA issues draft guidance on including tissue biopsies in clinical trials January 10, 2025Vol.51 No.01
Drugs & Targets FDA approves Ensacove for ALK-positive locally advanced or metastatic NSCLC January 10, 2025Vol.51 No.01
Drugs & Targets FDA approves Tevimbra + chemo for first-line treatment of gastric and GEJ cancers January 10, 2025Vol.51 No.01
Drugs & Targets FDA approves Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma January 10, 2025Vol.51 No.01
Drugs & Targets FDA approves Ryoncil for steroid-refractory acute graft versus host disease in pediatric patients January 10, 2025Vol.51 No.01
